Biohaven skids after BHV-7000 bipolar study failure

Biohaven Pharmaceuticals' Kv7.2/7.3 potassium channel activator BHV-7000 failed to meet the primary endpoint in a Phase III bipolar mania trial. The three-week study "did not statistically separate from the comparator" on the Young Mania Rating Scale primary outcome measure, the company said Monday.